Categories

Merck provides support for patients affected by COVID-19 pandemic

During this unprecedented time, Merck is committed to ensuring their medicines and vaccines reach their patients and customers. This includes supporting patients who might need more help today with their medications, including those who are unemployed or have lost insurance coverage due to the COVID-19 pandemic. To learn about what support options may be available, […]

Read More No Comments

Takeda Oncology changes name of their patient support program

Takeda Oncology announces that the name of their patient support program has changed from Takeda Oncology 1Point to Takeda Oncology Here2Assist™ effective May 18, 2020. Please note that only the name is changing. Patients and providers will continue to have the same high level of comprehensive, personalized support. Please review the important details regarding the change here:  Takeda […]

Read More No Comments

Merck announces that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers.

Merck Sharp & Dohme Corp. (“Merck”), a subsidiary of Merck & Co., Inc., is pleased to announce that ONTRUZANT® (trastuzumab-dttb) for injection, for intravenous use 21 mg/mL, a biosimilar* to Herceptin® (trastuzumab), is available through specialty distributors and wholesalers. Please contact your specialty distributor or wholesaler to confirm product availability. Before prescribing ONTRUZANT, please read the Prescribing Information, including the […]

Read More No Comments

REBLOZYL Approved by the FDA

The US Food and Drug Administration recently approved REBLOZYL® (luspatercept-aamt), the first and only erythroid maturation agent (EMA) indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of […]

Read More No Comments

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma

Released:  November 14, 2019 The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or stops responding, and the cancer cells continue […]

Read More No Comments

Merck announces new pack for KEYTRUDA®

Merck is pleased to announce the availability of a new pack for KEYTRUDA® (pembrolizumab)Injection 100 mg/4 mL (25 mg/mL) (“KEYTRUDA”).The new pack contains two 100mg/4 mL single-dose vials in a single carton. The price per vial of KEYTRUDA is not affected by the introduction of this new pack. The National Drug Code (NDC) for this […]

Read More No Comments

US Food and Drug Administration approves INREBIC® for Treatment

INREBIC® (fedratinib) capsules, a product from Celgene, is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INDICATION INREBIC® (fedratinib) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). IMPORTANT SAFETY […]

Read More No Comments

KEYTRUDA approved by FDA for first-line treatment of patients with HNSCC

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More No Comments

Pfizer announces a first-line combination Rx for advanced RCC.

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More No Comments

CMS finalizes rule which forces drug manufacturers to provide the list price for their products in direct-to-consumer ads.

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned…

Read More No Comments